MedPath

ANXIETY AND DEPRESSION DURING COVID-19 IN INDIA

Not yet recruiting
Conditions
B972||Coronavirus as the cause of diseases classified elsewhere
Registration Number
CTRI/2020/04/024784
Lead Sponsor
Dr Sameer Malhotra SELF SPONSORED NO CONFLICT OF INTEREST
Brief Summary

**Aim:**

1.To understand the prevalence of symptoms of Depression and Anxiety in general population during COVID-19 in India 2.To understand correlation between COVID-19 related factors and mental health symptomology in the general population in India Hypothesis: There is likelihood of significant symptoms of depression and anxiety among general population in India during the current COVID-19 outbreak. Procedure:  The participants would be selected with their informed consent. The objective of the study would be clearly written on Page 1 of the survey. The test would be administered electronically by all the participants individually only when consented to the study. The data collected will be kept strictly confidential and the identity of the participants will not be disclosed at any point of the research   Measures: 1. Demographic Information Demographic variables included Gender, Age, Place of Stay, Marital Status, Highest Level ofEducation, current living arrangement (e.g. staying alone or with family) and Occupation. It further includesregular employment status and current employment status(e.g, Work from home, temporary leave, termination etc) 2. History of illness (Present or past) History of physical ailment specified (diabetes, hypertension, heart ailment or being on any steroid or any other chronic ailment) Previous history of H1N1/ Influenza like illness 3. COVID-19 Information This section includes time spent focusing on COVID related information, current stressors with respect to COVID-19 and coping mechanisms used. This further includesinformation on resources available to participants near their place of stay and information of any known diagnosed case of COVID-19. 4. Standardized Scales to be used Generalized Anxiety Disorder Scale (GAD-7); Patient Health Questionnaire (PHQ-9)

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
1000
Inclusion Criteria

Participants of the age of 18 years and above Participants residing in India Participants with minimum 10 years of education with basic knowledge of English.

Exclusion Criteria

Participants under the age of 18 years Participants residing outside of India Participants with previous history of any major psychiatric illness, psychiatric hospitalization or currently on any psychiatric medication.Â.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To understand the prevalence (magnitude) of depression and anxiety of general adult population during COVID-19 using Generalized Anxiety Disorder Scale (GAD-7) and Patient Health Questionnaire (PHQ-9). Rise in Anxiety and Depression will be noted.1 month during the period of COVID-19 pandemic.
Secondary Outcome Measures
NameTimeMethod
Through the analysis of the results, it will help device psychological intervention/mental health programs geared towards general and specific symptoms and management of emotional needs can be provided to the general population during and post-crisis.1 month during the period of COVID-19 pandemic.

Trial Locations

Locations (1)

Max Super Speciality Hospital

🇮🇳

South, DELHI, India

Max Super Speciality Hospital
🇮🇳South, DELHI, India
Sameer Malhotra
Principal investigator
9810022980
sameer.malhotra@maxhealthcare.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.